Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=9
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=9
Search /vufind/Search2/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=9
PubPharm (7.806)
81
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma : A Phase 1 Study of JNJ-64407564, a Humanized GPRC5D * CD3 Bispecific Antibody in Japanese Subjects With Relapsed or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
82
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy : A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
83
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma : A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
84
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma : A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
85
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma : A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
86
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel : Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
87
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma : A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibition for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
88
A Study of Daratumumab : A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
89
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment : A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
90
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma : A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
[1]
« Vorheriger
4
5
6
7
8
9
10
11
12
13
14
Nächster »
[781]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
7.806
Aufsätze
7.806
E-Artikel
7.806
E-Ressourcen
Zeitschriftentitel
4.588
WHO International Clinical Trials Registry Plat...
3.218
ClinicalTrials.gov
Thema
7.806
610
6.935
Study Type: Interventional
3.170
Multiple Myeloma
2.647
Neoplasms, Plasma Cell
2.056
Recruitment Status: Not yet recruiting
1.944
Phase: Phase 2
1.671
Phase: Phase 3
1.520
Recruitment Status: Completed
1.376
Recruitment Status: Authorised-recruitment may ...
1.327
Recruitment Status: Recruiting
1.007
Medical Condition: Multiple Myeloma
985
Phase: Phase 1
775
Study Type: Observational
471
Recruitment Status: Active, not recruiting
397
Lymphoma
380
Recruitment Status: Terminated
316
Leukemia
258
Phase: Phase 1/Phase 2
250
Myelodysplastic Syndromes
234
Phase: Phase 1, Phase 2
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4.854
2020-
2.898
2010-2019
54
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
7.676
Englisch
88
Unbestimmt
14
Spanisch
8
Dänisch
8
Französisch
6
Deutsch
2
Tschechisch
2
Galizisch
2
Kinyarwanda
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...